Walgreens sees Rite Aid deal closing in early 2017
The exterior of the Walgreens store in Times Square is seen in New York, U.S., July 5, 2016. Picture taken July 5, 2016. REUTERS/Shannon Stapleton
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
By Sruthi Ramakrishnan
(Reuters) - Drugstore chain Walgreens (NASDAQ: WBA) said it expected its Rite Aid acquisition (NYSE: RAD) to close three months later than planned, and included the smaller rival's profit in its full-year forecast, suggesting the company expected the deal to win regulatory approval.
Shares of Walgreens Boots Alliance Inc, which also reported a better-than-expected quarterly profit, were up 3.7 percent at $80.04 on Thursday morning. Rite Aid's shares were up 4.5 percent at $6.96.
The No. 1 U.S. drugstore operator by store count said it expected to divest the 500-1,000 stores it needs to shed to win approval for the $9.4 billion acquisition by the end of 2016, and now expects the deal to close on Jan. 27.
Reports on Wednesday that supermarket chain Kroger Co (NYSE: KR) is questioning whether to proceed with buying divested stores from Walgreens cast doubts on the deal's future.
Multibillion-dollar deals, particularly in healthcare, have been facing more scrutiny from U.S. antitrust authorities recently, with many being scrapped or undergoing lengthy approval processes, for fear of creating a monopoly situation.
Walgreens forecast adjusted profit of $4.85-$5.20 per share for the fiscal year ending August 2017, which included 5-12 cents per share from Rite Aid.
"From the fact that we have included some part of Rite Aid potential profit now in our guidance, you can really understand that we are confident about this deal," Chief Executive Stefano Pessina said on a post-earnings conference call.
The midpoint of Walgreens' forecast range met the average analyst estimate of $5.02, according to Thomson Reuters I/B/E/S.
Walgreens wants to buy Rite Aid to widen its U.S. footprint and negotiate for lower drug costs.
"The longer the (merger) process takes the more likely it is to close as it signals a delay in sorting out the divestiture package vs. a true blockage by FTC," Evercore ISI analyst Ross Muken said.
Walgreens reported a profit of $1.07 per share in the fourth quarter ended Aug. 31, excluding items, beating the average analyst estimate of 99 cents.
Walgreens said in June it met its goal of achieving $1 billion in synergies from its Boots Alliance acquisition. It is also working on a multi-year plan to cut $1.5 billion in costs by its fiscal year end, including by closing about 200 stores and reorganizing operations.
Sales rose marginally to $28.64 billion, missing the average estimate of $29.06 billion.
(Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Martina D'Couto and Shounak Dasgupta)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelcase (SCS) Reports Preliminary Q3 EPS In-Line with Views, Revs Light
- American Airlines raises fourth-quarter unit revenue forecast
- Ferrellgas Partners (FGP) Tops Q1 EPS by 6c
Create E-mail Alert Related CategoriesEarnings, General News, Reuters
Related EntitiesEarnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!